Study On Jackfruit Seed Resistant Starch And Bifidobacterium Pseudolongum In Preventing And Relieving Hyperlipidemia In Mice

Hyperlipidemia is a chronic systemic metabolic disease,manifested by abnormal fat transport or metabolism,including decreased high-density lipoprotein(HDL)content,total cholesterol(TC),triglycerides(TG)and Low density lipoprotein(Low Density Lipoprotein,LDL)content increased,etc.Hyperlipidemia is considered to be one of the risk factors for heart disease,atherosclerosis and coronary diabetes mellitus.In the world,approximately 17 million people suffer from cardiovascular diseases caused by hyperlipidemia.The risk is extremely high but never Very good treatment.Resistant Starch(RS)is a common prebiotic.Studies have confirmed that it can be used to relieve hyperlipidemia,but there are also reports that RS has limited effects on host body weight and blood lipids,which may be due to neglect The interaction of RS with the intestinal flora and key utilization bacteria of the intestine.Intestinal microbes are considered to be the "second set of genomes" of the human body and are inextricably linked to various chronic metabolic diseases.The composition of the intestinal flora of patients with hyperlipidemia is significantly different from that of healthy people.It is characterized by low intestinal microbial diversity,specifically manifested in the increased abundance of actinomycetes,Proteus and Bacteroides The abundance of phylum is reduced.Therefore,aiming at the different composition of intestinal flora in patients with hyperlipidemia,using the synergistic effect of probiotics and prebiotics to target the regulation of intestinal microbial composition is expected to provide new ideas for alleviating/treatment of hyperlipidemia.However,domestic and foreign studies on the key bacteria using RS in the intestine and the synergistic mechanism between the two are still unclear.Therefore,this study takes jackfruit seeds resistant starch(Jackfruit Seeds Resistant Starch,JSRS)as the research object,and through the construction of a mouse hyperlipidemia model,objectively demonstrates the probiotic mechanism of intestinal microbes synergizing JSRS in all aspects,including 16 S r RNA amplicon sequencing,macro Genome sequencing,immune indicators,etc.This study includes two phased experiments.First,the first phase confirmed that JSRS can control the weight of mice by improving the intestinal microbiome of hyperlipidemia mice(such as Akkermansia,Ruminococcus and Bifidobacterium and other beneficial bacteria increase significantly).And effectively improve blood clinical indicators(TC,TC,HDL-C,LDL-C)and relieve.At this stage,it was found that JSRS promoted the growth of Bifidobacterium pseudolongum in the intestine.Then,through in vitro liquid culture experiments,it was confirmed that Bifidobacterium pseudolongum could use JSRS.For this reason,a 6-week in vivo verification experiment was carried out on C57B/6L mice in the second stage.Not only it was 10% JSRS added to the feed,but also Bifidobacterium pseudolongum was intragastrically administered to the experimental group of mice every day.Through the combined use of JSRS and Bifidobacterium pseudolongum,it was confirmed that the combined use of JSRS and Bifidobacterium pseudolongum not only improved the body weight,abdominal white fat and serum lipid levels of mice,but also has a preventive and therapeutic effect on liver steatosis of liver cells.In summary,this study reveals that the combined use of JSRS and Bifidobacterium pseudolongum can improve hyperlipidemia in mice,which will support the development of "synbiotics" and provide new opportunities for the prevention and treatment of hyperlipidemia.